Moreover, galectin-3 inhibitors have been shown to alleviate diabetes-associated cognitive impairment by reducing oxidative stress and neuroinflammation both in vivo and in vitro [18], which confirms the important role of galectin-3 in systemic inflammation. This evidence concerns the gene LGALS3 and Cognitive impairment.